Clinical trial · Interventional
The Clinical Significance of Ovarian Function Detection and Protection in Fertility Preservation Surgery for Ovarian Malignancy
NCT03882190CI-TRIAL-00037698unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The design of this prospective interventional study is to investigate the clinical significance of applying GnRHa preoperatively and postoperatively and detecting physical and endocrinic change in fertility preservation surgery
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Fertility Preservation Surgery | — | UNRESOLVED | — |
| Ovarian Malignancy | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| GnRHa | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- NO_INTERVENTION
- label
- group 1
- type
- EXPERIMENTAL
- label
- group 2
- interventionNames
- Drug: GnRHa
Primary outcomes (3)
- measure
- the content of FSH(mIU/mL), LH(mIU/mL), E2(pmol/L), P(nmol/L), T(nmol/L) and PRL(nmol/L)
- timeFrame
- 1 year during the perioperative period
- description
- by monitoring six above-mentioned hormones preoperatively and postoperatively, the ovarian function is evaluated
- measure
- the volume of ovary(cm*cm*cm)
- timeFrame
- 1 year during the perioperative period
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 1 Year
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: 1. Volunteer to participate in the study with informed consent; 2. Females aged 10-90 who are confirmed with ovarian malignancy and are willing to receive GnRHa experimentally to preserve their fertility function. Exclusion Criteria: 1. Pregnancy, lactation and postmenopause; 2. Suspected or identified as other tumors of genital tract; 3. History of hyperparathyroidism, infectious diseases (tuberculosis, AIDS), autoimmune diseases, or digestive system diseases (malabsorption, crohn disease and dysentery); 4. Other diseases or heavy injuries that will interfere with the results; 5. Simultaneous participation in another clinical study with investigational medicinal product(s) or researcher thinks the subjects are not suitable for this trial.
References
Publications (0)
Data not yet available
No reference posted for this study.